Recombinant HCMV and RHCMV vectors and uses thereof
AssigneeOregon Health & Science University
InventorsLouis Picker, Jay A. Nelson, Klaus Frueh, Michael A. Jarvis, Scott G. Hansen
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread.
Claims10
A recombinant viral vector comprising a nucleic acid sequence encoding a human cytomegalovirus (HCMV) backbone vector and at least one heterologous antigen, wherein:
- (a) the at least one heterologous antigen is a pathogen-specific antigen or a tumor antigen;
- (b) the recombinant viral vector comprises a deletion in the HCMV UL115 gene that eliminates expression of a functional gL protein;
- and
- (c) the recombinant viral vector comprises a deletion in the UL128 gene, a deletion in the UL130 gene, a deletion in the UL146 gene, and a deletion in the UL147 gene.
Dependencies are inferred from the claim text.